Our blog

An established pharmaceutical company in Europe that develops, manufactures and markets generic medications planned to continue its growth strategy by opening a new subsidiary to target the US generics market. To develop and commercialise a portfolio of generic drugs to market, the company needed a US General Manager.

In 2019, the US biosimilar market was worth $737.2 million and continues to grow with a CAGR of 46.2% forecast for 2020-2027, however many are frustrated at the current rate of adoption in the US. But with increasing healthcare costs and a growing debt from Covid-19, what does the next year hold for biosimilar adoption across the US?

As part of our ‘Female Leaders: Inspiring Together’ series, we interviewed Rachel McNeill – Founder & CEO at PharmaPhix – about her new pharma services company and why she feels society’s biggest challenge is accepting that we all have an equal role in balancing work and family life regardless of gender.

As part of our ‘Female Leaders: Inspiring Together series, we interviewed Emmanuelle Lepine – General Manager at mAbxience – about becoming a CEO of a pharma company before the age of 40 and how she learnt the hard way not to push yourself past your limits.

As part of our ‘Female Leaders: Inspiring Together’ series, we interviewed Ella Sigga Gudlaugsdottir – Vice President Human Resources at Alvotech – about how she encourages more diversity in every organisation she joins and why she sometimes finds it difficult to maintain a work-life balance

As part of our ‘Female Leaders: Inspiring Together’ series, we interviewed Berit Lindholm – CEO for Bluefish Pharma – about how she started her career in pharmaceuticals, her greatest achievements and why she initially turned down a CEO role.

As part of our ‘Female Leaders: Inspiring Together’ series, we interviewed Miranda Heining – General Manager Belgium & The Netherlands for Fresenius Kabi – about her journey, accomplishments and why you should never worry about trying to be perfect!

The emergence of covid-19 and resulting lockdowns sparked fears for the global supply of generics and biosimilars. With the industry being heavily reliant on China for APIs and India for the manufacture of generic drugs, the disruption caused by covid-19 had the potential to wreak havoc across the whole supply chain.